Antibe Therapeutics Inc.  (ATE:TSX) Analysts rate as a Buy, $2.86 target

STA Research
by: STA Research
Antibe Therapeutics Inc.

Antibe Therapeutics Inc. Stock Analysis:

Based on the Antibe Therapeutics Inc. stock forecasts from 6 analysts, the average analyst target price for Antibe Therapeutics Inc. is $1.10 over the next 12 months. Antibe Therapeutics Inc.’s average analyst rating is Buy. Stock Target Advisor’s own stock analysis of Antibe Therapeutics Inc. is Slightly Bearish, which is based on 2 positive signals and 4 negative signals. At the last closing, Antibe Therapeutics Inc.’s stock price was CAD 0.61Antibe Therapeutics Inc.’s stock price has changed by +8.93% over the past week, -1.61% over the past month and -40.78% over the last year.

What we like:

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What we don’t like:

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector


Stock Target Advisor is not a broker/dealer, investment advisor, or platform for making stock buying or selling decisions. Our goal is to democratize and simplify financial information through automated analysis, aggregation of stock information, and education to help investors with their research. No content on our site, blogs or newsletters constitutes – or should be understood as constituting – a recommendation to enter into any securities transactions or to engage in any of the investment strategies presented in our site content. We also cannot guarantee the accuracy of any information presented on our site and in our analysis.

Leave a Reply

Your email address will not be published.